Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Glycomine, Inc.

Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
From Glycomine, Inc.
Via Business Wire
Glycomine Receives FDA Fast Track Designation for GLM101 for the Treatment of PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Announces Encouraging Efficacy Data from Ongoing Phase 2 Clinical Study in PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Announces First Pediatric Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Presents at ASHG 2023 Data from Ongoing Natural History Study with Insight into Genetic Mutations and Biomarkers for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Appoints Dr. Rose Marino Chief Medical Officer
From Glycomine, Inc.
Via Business Wire
Data from Glycomine’s Ongoing Natural History Study Provides Insight into Clinical Measures and Biomarkers for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine Announces First Dosing in Phase 1 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG
From Glycomine, Inc.
Via Business Wire
Glycomine’s Natural History Study Informs Potentially Lifesaving Update to Standard of Care for PMM2-CDG Patients
From Glycomine, Inc.
Via Business Wire
Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease
From Glycomine, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.